PMC:7497282 / 47439-48974 JSONTXT

{"project":"MyTest","denotations":[{"id":"32741232-26404632-29927086","span":{"begin":36,"end":38},"obj":"26404632"},{"id":"32741232-28690915-29927087","span":{"begin":438,"end":440},"obj":"28690915"},{"id":"32741232-26382043-29927088","span":{"begin":494,"end":496},"obj":"26382043"},{"id":"32741232-27760579-29927089","span":{"begin":668,"end":670},"obj":"27760579"},{"id":"32741232-27831742-29927090","span":{"begin":804,"end":806},"obj":"27831742"},{"id":"32741232-30288417-29927091","span":{"begin":1230,"end":1232},"obj":"30288417"},{"id":"32741232-28437234-29927092","span":{"begin":1371,"end":1373},"obj":"28437234"},{"id":"32741232-28606811-29927093","span":{"begin":1531,"end":1533},"obj":"28606811"}],"namespaces":[{"prefix":"_base","uri":"https://www.uniprot.org/uniprot/testbase"},{"prefix":"UniProtKB","uri":"https://www.uniprot.org/uniprot/"},{"prefix":"uniprot","uri":"https://www.uniprot.org/uniprotkb/"}],"text":"Using the updated integrated model [51], KRI performed an uncertainty and sensitivity analysis of cost assumptions [59] that continued to demonstrate the relatively high cost of IPV. Recognizing the importance of maintaining high population immunity for serotypes 1 and 3 prior for future coordinated bOPV cessation, KRI demonstrated the benefits of high levels of continued bOPV use and sustaining OPV production through bOPV cessation [60]. Building on prior characterization of iVDPV risks [50], KRI modeled the impact of comprehensive screening to find and treat asymptomatic iVDPV excretors and explored the impact of screening on the expected benefits of PAVDs [61]. KRI explored the potential benefits of investments in a new, ideal poliovirus vaccine assuming the best attributes of OPV and IPV [62]. Emphasizing the importance of actions taken by countries and the GPEI, KRI highlighted the importance of maintaining preparedness throughout the polio endgame [63]. KRI also demonstrated the minor role of IPV in outbreak response when used in conjunction with OPV, and showed that IPV in addition to OPV for outbreak response (in the outbreak area) does not represent a cost-effective option compared to using OPV alone [64]. KRI demonstrated the need to maintain sufficient poliovirus vaccine supplies and stockpiles for outbreak response in the polio endgame [65] and assessed the economic benefits of temporary recommendations for international travel immunization requirements for countries with transmission of WPV1 [66]."}

{"project":"2_test","denotations":[{"id":"32741232-26404632-29927086","span":{"begin":36,"end":38},"obj":"26404632"},{"id":"32741232-28690915-29927087","span":{"begin":438,"end":440},"obj":"28690915"},{"id":"32741232-26382043-29927088","span":{"begin":494,"end":496},"obj":"26382043"},{"id":"32741232-27760579-29927089","span":{"begin":668,"end":670},"obj":"27760579"},{"id":"32741232-27831742-29927090","span":{"begin":804,"end":806},"obj":"27831742"},{"id":"32741232-30288417-29927091","span":{"begin":1230,"end":1232},"obj":"30288417"},{"id":"32741232-28437234-29927092","span":{"begin":1371,"end":1373},"obj":"28437234"},{"id":"32741232-28606811-29927093","span":{"begin":1531,"end":1533},"obj":"28606811"}],"text":"Using the updated integrated model [51], KRI performed an uncertainty and sensitivity analysis of cost assumptions [59] that continued to demonstrate the relatively high cost of IPV. Recognizing the importance of maintaining high population immunity for serotypes 1 and 3 prior for future coordinated bOPV cessation, KRI demonstrated the benefits of high levels of continued bOPV use and sustaining OPV production through bOPV cessation [60]. Building on prior characterization of iVDPV risks [50], KRI modeled the impact of comprehensive screening to find and treat asymptomatic iVDPV excretors and explored the impact of screening on the expected benefits of PAVDs [61]. KRI explored the potential benefits of investments in a new, ideal poliovirus vaccine assuming the best attributes of OPV and IPV [62]. Emphasizing the importance of actions taken by countries and the GPEI, KRI highlighted the importance of maintaining preparedness throughout the polio endgame [63]. KRI also demonstrated the minor role of IPV in outbreak response when used in conjunction with OPV, and showed that IPV in addition to OPV for outbreak response (in the outbreak area) does not represent a cost-effective option compared to using OPV alone [64]. KRI demonstrated the need to maintain sufficient poliovirus vaccine supplies and stockpiles for outbreak response in the polio endgame [65] and assessed the economic benefits of temporary recommendations for international travel immunization requirements for countries with transmission of WPV1 [66]."}